Tscan Therapeutics Inc (NASDAQ:TCRX) shares, rose in value on Friday, June 20, with the stock price down by -1.37% to the previous day’s close as strong demand from buyers drove the stock to $1.44.
Actively observing the price movement in the last trading, the stock closed the session at $1.46. Referring to stock’s 52-week performance, its high was $7.89, and the low was $1.02. On the whole, TCRX has fluctuated by 19.01% over the past month.
With the market capitalization of Tscan Therapeutics Inc currently standing at about $81.49 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TCRX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TCRX currently trading nearly -7.87% and -1.74% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.26, while the 7-day volatility ratio is showing 2.51% which for the 30-day chart, stands at 5.77%. Furthermore, Tscan Therapeutics Inc (TCRX)’s beta value is 0.98, and its average true range (ATR) is 0.14.
A comparison of Tscan Therapeutics Inc (TCRX) with its peers suggests the former has fared considerably weaker in the market. TCRX showed an intraday change of -1.37% in last session, and over the past year, it shrunk by -80.65%%.
Data on historical trading for Tscan Therapeutics Inc (NASDAQ:TCRX) indicates that the trading volumes over the past 3 months, they’ve averaged 572.72K. According to company’s latest data on outstanding shares, there are 52.31 million shares outstanding.
Nearly 22.56% of Tscan Therapeutics Inc’s shares belong to company insiders and institutional investors own 71.46% of the company’s shares. The stock has fallen by -52.63% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TCRX stock heading into the next quarter.
